Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 23, 2004. The report details changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) resulting from employee benefit plan transactions.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions within employee trusts and retirement plans.
Material Changes
The following specific equity movements were reported:
- Employee Share Option Plan: The GSK Trust transferred 227,586 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Mid-Term Incentive Plan: The GSK Trust sold 761 Ordinary Shares on behalf of participants at a price of £11.2610 per share and transferred an additional 1,093 Ordinary Shares to participants.
- US Retirement Savings Plan: The number of Ordinary Share ADRs held by the fund increased from 18,505,813 to 18,670,390 due to fund movements, with an average price of $43.27.
Management Commentary and Risks
Management notes that the GSK Trust and the US Retirement Savings Plan are discretionary funds where all employees or former employees are potential beneficiaries. Consequently, directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe hold indirect interests in these shares in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding the company's operations were disclosed in this filing.
Investor Verification Checklist
- Verify the total number of shares held in the GSK Trust and US Retirement Savings Plan to assess potential dilution or voting power changes.
- Confirm the specific shareholding percentages of directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe within these discretionary trusts.
- Review the full terms of the SmithKline Beecham Employee Share Option Plan 1991 and Mid-Term Incentive Plan to understand vesting schedules and future issuance obligations.